Neumora Therapeutics IPO Presentation Deck
NMRA-NLRP3 for Parkinson's Disease
Pharmacology
Focused on inhibiting the NLRP3 inflammasome to
modulate the immune response in neurodegeneration
Indication
Parkinson's disease (PD)
Epidemiology
~1 million people in the U.S. have PD¹
Status
Discovery stage; identified small molecule series
showing potency, on-target selectivity & CNS
penetrance
1) Yang et al. NPJ Parkinsons Dis. 2020; 6: 15.
Strong Biological
Rationale
NLRP3
inflammasome is
activated in
microglia in
response to disease
linked proteins such
as a-synuclein,,
leading to
proinflammatory
signaling in
neurodegeneration
diseases
ECM
Microglia
Toxic
a-synuclein
aggregates
Dysfunctional
mitochondria
NMRA-
NLRP3
mitoROS
Inhibits
NLRP3
NLRP3
NLRP3
inflammasome
complex formation
PD PATHOLOGY
Neurodegeneration
O IL-1B
Cleavage
Pro-inflammatory
cytokine release
(e.g., IL-13)
Pro
IL-13
Endogenous pathways
Enhanced in disease
<-/● Drug impact
Confidential
24View entire presentation